Please login to the form below

Not currently logged in
Email:
Password:

Bayer abandons Nexavar for NSCLC

Bayer Healthcare and Onyx Pharmaceuticals have stopped a late-stage trial of Nexavar in patients with non-small cell lung cancer (NSCLC) as the drug did not improve survival rates in patients.

Bayer Healthcare and Onyx Pharmaceuticals have stopped a late-stage trial of Nexavar in patients with non-small cell lung cancer (NSCLC) as the drug did not improve survival rates in patients.

The independent Data Monitoring Committee (DMC) concluded during a planned interim analysis that the study would not meet its primary endpoint of improved overall survival.

The Phase III ESCAPE (Evaluation of Sorafenib, Carboplatin And Paclitaxel Efficacy in NSCLC) trial evaluated Nexavar when administered in combination with the chemotherapeutic agents carboplatin and paclitaxel in patients with NSCLC.

Although safety events were generally consistent with those previously reported, higher mortality was observed in the subset of patients with squamous cell carcinoma of the lung treated with sorafenib and carboplatin and paclitaxel compared with those treated with carboplatin and paclitaxel alone.

Bayer and Onyx will now further review the analysis to determine if the results will impact other ongoing Nexavar lung cancer trials.

Nexavar is already approved in Europe, the US and Japan for treating kidney and in the US and Europe for liver cancer.

18th February 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics